Get the Stockscreener App
10.05
2.05%
-0.21
After Hours:
10.05
Mineralys Therapeutics Inc stock is traded at $10.05, with a volume of 224.98K.
It is down -2.05% in the last 24 hours and down -22.99% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
See More
Previous Close:
$10.26
Open:
$10.21
24h Volume:
224.98K
Relative Volume:
1.00
Market Cap:
$500.18M
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-3.6813
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
-2.14%
1M Performance:
-22.99%
6M Performance:
-10.03%
1Y Performance:
-18.16%
1-Day Range:
$9.99
$10.38
1-Week Range:
$9.81
$10.90
52-Week Range:
$8.58
$16.91
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
10.05 | 500.18M | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Clinical Trials News Live Feed - StockTitan
Jennison Associates LLC Has $13.32 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial - MSN
Hypertension Drug Developer Mineralys Therapeutics Announces Critical Q4 Earnings Date - StockTitan
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025 - Marketscreener.com
Mineralys Therapeutics to Announce Fourth Quarter and Full - GlobeNewswire
Mineralys Completes Enrollment in Mid-Stage Hypertension Trial -February 04, 2025 at 11:43 am EST - Marketscreener.com
Mineralys Therapeutics Completes Enrollment in Explore-CKD - GlobeNewswire
Mineralys Therapeutics, Inc. Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3B CKD and Albuminuria - Marketscreener.com
Mineralys completes enrollment for hypertension drug trial - Investing.com India
Mineralys completes enrollment for hypertension drug trial By Investing.com - Investing.com South Africa
Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria - Marketscreener.com
Mineralys Therapeutics completes enrollment in Explore-CKD Phase 2 trial - TipRanks
Mineralys Therapeutics Completes Enrollment for Key Trial - TipRanks
Breakthrough CKD Trial Fully Enrolled: Mineralys Targets Silent Killer in Kidney Patients - StockTitan
Mineralys Therapeutics (NASDAQ:MLYS) Shares Up 5.1%What's Next? - MarketBeat
(MLYS) Technical Data - Stock Traders Daily
Mineralys Therapeutics Appoints Dr. Alexander Gold to Board Amid Hypertension Drug Development - MSN
Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension - Seeking Alpha
Barclays PLC Grows Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Holdings Boosted by Barclays PLC - Defense World
When (MLYS) Moves Investors should Listen - Stock Traders Daily
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy Sells 10,757 Shares - MarketBeat
Insider Sell: CEO Jon Congleton Sells Shares of Mineralys Therap - GuruFocus.com
Insider Sell: Adam Levy Sells Shares of Mineralys Therapeutics I - GuruFocus.com
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells $166,096.98 in Stock - MarketBeat
Mineralys Therapeutics CEO Jon Congleton sells $166,082 in stock By Investing.com - Investing.com Nigeria
Mineralys therapeutics CFO Adam Levy sells $97,863 in stock By Investing.com - Investing.com Australia
Mineralys Therapeutics CEO Jon Congleton sells $166,082 in stock - Investing.com India
Mineralys therapeutics CFO Adam Levy sells $97,863 in stock - Investing.com
Overcoming Barriers in Obesity and Hypertension Management: Practical Strategies for Physicians - Patient Care Online
Mineralys Therapeutics Receives FDA Clearance for Phase 2 Trial of Lorundrostat in Treating Sleep Apnea and Hypertension - MSN
Jane Street Group LLC Has $192,000 Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MyChesCo
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with HypertensionRADNOR, PA – January 8, 2025 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company f - Defense World
Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials - Yahoo Finance
Mineralys Therapeutics gets FDA nod for sleep apnea drug trial By Investing.com - Investing.com Nigeria
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat - Diagnostic and Interventional Cardiology
Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 9.6%Here's Why - MarketBeat
Mineralys Therapeutics : Corporate Overview January 2025 - Marketscreener.com
Mineralys Therapeutics Announces Phase 2 Clinical Trial of - GlobeNewswire
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension - Marketscreener.com
Mineralys Therapeutics gets FDA nod for sleep apnea drug trial - Investing.com
Mineralys Gets FDA Green Light for Sleep Apnea Drug Trial, Targets 54M Patient Market - StockTitan
Objective long/short (MLYS) Report - Stock Traders Daily
Neumora shares sink following Phase III flop in MDD - MSN
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Bought by Geode Capital Management LLC - Defense World
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):